AOD-9604 Information & Coordination for Licensed U.S. Clinics
Phoenix Meds Inc. helps licensed U.S. healthcare organizations manage the administrative side of professional AOD-9604 inquiries.
Our role includes clinic verification, documentation organization, access to publicly available regulatory information, and administrative communication with independent licensed pharmacies.
AOD-9604 is a synthetic peptide related to a fragment of human growth hormone. FDA describes AOD-9604 free base as a 16-amino-acid peptide consisting of the hGH 177–191 fragment with an additional tyrosine at the N-terminal end.
For clinics reviewing AOD-9604, substance identity, formulation, documentation, pharmacy information, and current FDA context all matter.
How Phoenix Meds Supports AOD-9604 Inquiries
A professional inquiry can involve clinic credentials, formulation records, pharmacy documentation, regulatory information, and questions that require follow-up. Phoenix Meds helps keep those administrative pieces organized. Our support may include:
- professional and facility credential verification;
- organization of available formulation and pharmacy documentation;
- review of labeling and substance-identity information;
- access to publicly available FDA and regulatory materials; and
- administrative communication with independent licensed pharmacies.
The goal is to give clinic teams a clearer administrative record and a more organized way to identify what information is available, what may be missing, and which questions require further professional review.
For related information, licensed healthcare facilities may review our medication information directory.
Current FDA and 503A Context
The nominations for AOD-9604-related bulk drug substances were withdrawn, but FDA chose to evaluate AOD-9604 free base and AOD-9604 acetate on its own initiative.
In December 2024, FDA concluded that the evaluation criteria weighed against placing either AOD-9604 free base or AOD-9604 acetate on the section 503A Bulks List and proposed that neither be included.
The Pharmacy Compounding Advisory Committee also voted against recommending inclusion. Advisory committee recommendations are non-binding and should not be described as a final FDA ban.
FDA’s current safety-risk page lists AOD-9604 under “Bulk drug substances nominated but withdrawn.
For clinics, the practical point is that the name “AOD-9604” by itself does not establish FDA approval or the regulatory status of a particular preparation.
What Licensed Clinics Should Know
FDA has evaluated AOD-9604 free base and AOD-9604 acetate as separate bulk drug substances.
According to FDA’s review materials, neither substance is a component of an FDA-approved drug.
FDA evaluated both forms for the treatment of obesity as part of its section 503A Bulks List review.
The agency identified limitations in the available evidence, along with concerns involving characterization and safety information.
AOD-9604 should therefore not be presented as an FDA-approved obesity treatment, an established weight-loss therapy, or a preparation with automatically established compounding eligibility.
Evidence and Safety Considerations
FDA reviewed clinical studies involving AOD-9604 in connection with obesity.
The agency found limited evidence of effectiveness. Several studies reviewed by FDA did not demonstrate statistically significant weight reduction compared with placebo, and the larger OPTIONS study did not show a significant difference in its primary weight-loss endpoint.
FDA also identified limited clinical safety information.
Because AOD-9604 is a peptide, FDA noted potential concerns involving immunogenicity, peptide-related impurities, aggregation, and active-ingredient characterization.
FDA’s current safety-risk information also notes serious adverse events that may be associated with AOD-9604 while stating that causality has not been established.
These findings do not support describing AOD-9604 as proven safe, effective, well tolerated, or clinically established for weight loss or metabolic treatment.
Why Documentation Matters
“AOD-9604” does not describe every aspect of a preparation. FDA separately evaluated AOD-9604 free base and AOD-9604 acetate, making accurate substance identification important when reviewing professional documentation. Relevant records may include:- the identified AOD-9604 form;
- formulation details;
- labeling;
- pharmacy or facility information;
- available lot or batch information;
- certificates of analysis or other pharmacy-provided records; and
- relevant regulatory documentation.
AOD-9604 Administrative Coordination for Licensed Clinics
Licensed U.S. healthcare organizations reviewing an AOD-9604-related professional inquiry can use Phoenix Meds for clinic verification, documentation organization, and administrative pharmacy communication.
Clinic Verification
Documentation Review
Available formulation, labeling, pharmacy-provided, and regulatory documentation can be organized into a clearer professional record.
Pharmacy Coordination
Where appropriate, Phoenix Meds can support administrative communication between a verified licensed clinic and an independent licensed pharmacy. Prescribing, compounding, distribution, dispensing, storage, and other regulated activities remain with the licensed parties.
Frequently Asked Questions
Is AOD-9604 FDA-approved?
FDA’s review materials state that neither AOD-9604 free base nor AOD-9604 acetate is a component of an FDA-approved drug.
What is the current FDA context for AOD-9604?
The original nominations were withdrawn, but FDA chose to evaluate AOD-9604 free base and AOD-9604 acetate on its own initiative.
In its December 2024 review, FDA concluded that the available information weighed against adding either substance to the 503A Bulks List. The Pharmacy Compounding Advisory Committee also voted against recommending inclusion.
These findings should not be described as FDA approval or as a blanket product-specific ban.
What can Phoenix Meds help my clinic with?
Phoenix Meds supports licensed healthcare organizations with clinic verification, documentation organization, publicly available regulatory information, and administrative coordination related to professional AOD-9604 inquiries.
Can Phoenix Meds assist with pharmacy communication?
Phoenix Meds can support administrative communication between a verified licensed clinic and an independent licensed pharmacy where appropriate. The pharmacy remains responsible for its own professional, regulatory, and product-specific decisions.
Can Phoenix Meds help organize a COA or other supporting documentation?
Yes. Phoenix Meds can help organize available pharmacy-provided records, formulation details, labeling, lot or batch information, certificates of analysis, and other supporting documents when they are made available. Phoenix does not independently verify or certify the testing results or the quality of a preparation.
Does Phoenix Meds handle dispensing, fulfillment, or shipping?
No. Phoenix Meds does not manufacture, compound, prescribe, dispense, sell, ship, test, or take custody of medications.
Those activities remain with the appropriately licensed entities responsible for performing them.
Important Notice
Phoenix Meds Inc. provides administrative coordination and documentation support for licensed U.S. healthcare organizations.
We are not a pharmacy, medical practice, manufacturer, wholesaler, distributor, prescriber, or dispensing entity. We do not manufacture, compound, prescribe, dispense, sell, ship, test, or take custody of medications.
Information on this page is provided for professional and administrative purposes and does not constitute medical advice, FDA approval, a prescribing recommendation, or a product-specific legal determination.